2017-10-31T10:02:27-05:00 2016-12-31 221430039 SOBEL & CO LLC CPA'S 293 EISENHOWER PARKWAY LIVINGSTON NJ 070391711 990 2016-01-01 208735688 SOLVING KIDS CANCER INC SOLV 2125886624 1 EAST 53RD STREET 5TH FLOOR NEW YORK NY 10022 SCOTT KENNEDY EXECUTIVE DIRECTOR 2125886624 2017-10-30 1 BRIDGET HARTNETT P01429163 9739949494 2017-09-24 96.225.92.15 2017-10-30 16:05:57 ED P 0FFB1CC1F4CCDACF95DFBECC59B6E52C80CE33BA 0784671A72E62D56CA58F66C0377D820D16B6C36 2016 2021-01-29 14:40:06Z SCOTT KENNEDY 1 EAST 53RD STREET 5TH FLOOR NEW YORK NY 10022 1328718 0 X WWW.SOLVINGKIDSCANCER.ORG X 2006 NY SOLVING KIDS' CANCER IMPROVES SURVIVAL OUTCOMES FOR THE DEADLIEST CHILDHOOD CANCERS BY CONTINUOUSLY INFLUENCING, ACCELERATING AND SUPPORTING NOVEL CLINICAL RESEARCH THAT DIRECTLY IMPACTS CHILDREN AS MORE EFFECTIVE AND LESS TOXIC TREATMENTS. 100% OF NON-BOARD (PUBLIC) DONATIONS ARE USED FOR FUNDING OUR MISSION PROGRAMS AND PROJECTS. 6 5 4 17 0 0 761768 903826 0 0 5202 4821 -31332 259838 735638 1168485 395420 456965 0 0 570204 457770 0 0 184921 338552 298611 1304176 1213346 -568538 -44861 2567323 2479739 55418 12695 2511905 2467044 X SOLVING KIDS' CANCER IMPROVES SURVIVAL OUTCOMES FOR THE DEADLIEST CHILDHOOD CANCERS BY CONTINUOUSLY INFLUENCING, ACCELERATING AND SUPPORTING NOVEL CLINICAL RESEARCH THAT DIRECTLY IMPACTS CHILDREN AS MORE EFFECTIVE AND LESS TOXIC TREATMENTS. 100% OF NON-BOARD (PUBLIC) DONATIONS ARE USED FOR FUNDING OUR MISSION PROGRAMS AND PROJECTS. 0 0 760800 456965 SKC ACTIVELY PURSUES THE UNDERSTANDING OF THE RESEARCH LANDSCAPE FOR NEUROBLASTOMA, HIGH-RISK BRAIN TUMORS AND SARCOMAS AND DEVELOPS CLINICAL RESEARCH PROGRAMS TO ADDRESS THE CURRENT UNMET NEEDS OF CHILDREN CURRENTLY AFFECTED BY THESE DISEASES AND CHILDREN YET TO BE DIAGNOSED. SURVIVAL RATES REMAIN UNSATISFACTORILY LOW FOR THE DEADLIEST CHILDHOOD CANCERS AND SKC PRIORITIZES THE DELIVERY OF TRANSFORMATIVE, NEXT-GENERATION CANCER THERAPIES TO THIS POPULATION THAT INCLUDES IMMUNOTHERAPY, VACCINES, CELLULAR THERAPY, NOVEL/SYNERGISTIC COMBINATION TREATMENTS, NEW TARGETED DRUGS, INTERVENTIONAL RADIOLOGY TECHNIQUES AND NOVEL THERAPY DELIVERY MECHANISMS. OUR CRITERIA FOR IDENTIFYING AND SUPPORTING THESE NOVEL APPROACHES AIMS TO PROVIDE MORE EFFECTIVE AND LESS TREATMENT OPTIONS THAN THE CURRENT STANDARD-OF-CARE. SKC HAS HELPED TO DEVELOP 23 CLINICAL TRIALS FOR CHILDREN RESULTING IN 22 NEW EXPERIMENTAL TREATMENT OPTIONS FOR CHILDREN WITH HIGH-RISK CANCERS. IN 2016, SKC HELPED PRIORITIZE, DEVELOP AND GRANT SUPPORT SEVERAL IMPORTANT MISSION PROGRAMS INCLUDING: A TRANSLATIONAL THERAPEUTIC DEVELOPMENT PROJECT OF A NANOPARTICLE FORMULATION OF THE ACTIVE COMPONENT (SN38) OF THE CYTOTOXIC AGENT IRINOTECAN THAT WILL SIGNIFICANTLY INCREASE EFFECTIVENESS AND REDUCE TOXICITY; A PH I CLINICAL TRIAL OF A PRECISION MEDICINE THERAPY (LORLATINIB) FOR HIGH-RISK SOLID TUMORS THAT EXPRESS THE ALK ONCOGENE MUTATION AFTER GENOMIC ANALYSIS; A PH IB CLINICAL TRIAL OF ONCOLYTIC VIRUS IMMUNOTHERAPY USING A GENETICALLY MODIFIED MEASLES VIRUS IN CHILDREN WITH HIGH-RISK BRAIN TUMORS; A PH I CLINICAL TRIAL USING A PATIENT'S OWN T-CELLS MODIFIED WITH 4 TUMOR ANTIGENS FOR CHILDREN WITH NEUROBLASTOMA AND SARCOMAS; AND A PH I CLINICAL TRIAL INVESTIGATING THE COMBINATION OF AN ANTI-PD1 CHECKPOINT INHIBITOR AND AN ANTI-CTLA4 CHECKPOINT INHIBITOR IN CHILDREN WITH HIGH-GRADE BRAIN TUMORS. 760800 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 9 0 1 4 1 0 0 0 0 0 1 1 0 0 0 0 X 6 5 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NY X THE ORGANIZATION 2125886624 1 EAST 53RD STREET 5TH FLOOR NEW YORK NY 10022 JOHN LONDON CHAIRMAN, CO-FOUNDER 2.00 X X 0 0 0 SCOTT KENNEDY EXECUTIVE DIRECTOR, CO-FOU 40.00 X X 150000 0 27147 KHALIL BARRAGE DIRECTOR 2.00 X 0 0 0 CATHERINE LONDON CO-FOUNDER, DIRECTOR 2.00 X 0 0 0 CHANNING STAVE SECRETARY 2.00 X X 0 0 0 MARK SAVOYE TREASURER 2.00 X 0 0 0 150000 0 27147 1 0 1 0 0 222497 681329 903826 4821 4821 420071 222497 160233 259838 259838 1168485 0 0 264659 456965 456965 177147 177147 220110 31760 41250 147100 37240 7965 5262 24013 23273 13036 5001 5236 40777 40777 115965 65250 50386 329 8280 8280 62792 62792 10351 8415 1660 276 37111 37111 4287 4287 MISCELLANEOUS 6858 5255 1603 WEB DESIGN, HOSTING, AN 5079 1836 3243 PRINTING AND SHIPPING 2707 2707 DATABASE EXPENSE 2088 2088 2316 262 1640 414 1213346 760800 267625 184921 99538 226474 2300960 2181077 77000 10720 18843 24064 221352 187533 64547 33819 6435 3585 2567323 2479739 55418 12695 55418 12695 X 2078455 1680427 433450 786617 2511905 2467044 2567323 2479739 -44861 0 X X 0 1 X 1 0 X 738702 309184 1381381 761768 1198351 4389386 738702 309184 1381381 761768 1198351 4389386 267312 4122074 11123 7027 5638 5202 4821 33811 4423197 0.93190 0.88680 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 5160 5160 0 216192 182373 33819 33819 X 1168485 0 1168485 0 1168485 1213346 0 1213346 0 1213346 PART X, LINE 2: THE ORGANIZATION FOLLOWS STANDARDS THAT PROVIDE CLARIFICATION ON ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES RECOGNIZED IN THE ORGANIZATION'S FINANCIAL STATEMENTS. THE GUIDANCE PRESCRIBES A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR THE RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, AND ALSO PROVIDES GUIDANCE ON DERECOGNITION, CLASSIFICATION, INTEREST AND PENALTIES, DISCLOSURE AND TRANSITION. THE ORGANIZATION'S POLICY IS TO RECOGNIZE INTEREST AND PENALTIES ON UNRECOGNIZED TAX BENEFITS IN INCOME TAX EXPENSE. NO INTEREST AND PENALTIES WERE RECORDED DURING 2016 AND 2015. AT DECEMBER 31, 2016 AND 2015, THERE ARE NO SIGNIFICANT INCOME TAX UNCERTAINTIES. SPRING CELEBRATION 642568 222497 420071 102265 57966 642568 222497 420071 102265 57966 160231 259840 1 BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA HOUSTON TX 77030 741613878 501(C)(3) 130000 CASH CANCER RESEARCH MEMORIAL SLOAN KETTERING CANCER CENTER 633 THIRD AVENUE 28TH FLOOR NEW YORK NY 10017 131924236 501(C)(3) 20000 CASH CANCER RESEARCH DUKE UNIVERSITY BOX 104008 DURHAM NC 27705 560532129 501(C)(3) 64408 CASH CANCER RESEARCH CHILDREN'S HOSPITAL OF PHILADELPHIA 3615 CIVIC CENTER BLVD 142-B PHILADELPHIA PA 191044318 231352166 501(C)(3) 176557 CASH CANCER RESEARCH CHILDREN'S HOSPITAL OF LOS ANGELES 4650 SUNSET BLVD LOS ANGELES CA 90027 951690977 501(C)(3) 66000 CASH CANCER RESEARCH 5 PART I, LINE 2: THE ORGANIZATION EXPENDS FUNDS IN CONNECTION WITH GRANT COMMITMENTS AS EACH GRANTEE ACCOMPLISHES SPECIFIC MILESTONES SET FORTH IN EACH GRANT AGREEMENT. EACH GRANTEE IS REQUIRED TO SUBMIT PROGRESS REPORTS ON A PERIODIC BASIS AS MILESTONES ARE ACHIEVED PURSUANT TO THE GRANT AGREEMENTS. X X X 0 0 0 0 0 0 0 0 0 SCOTT KENNEDY EXECUTIVE DIRECTOR, CO-FOU 150000 0 0 0 0 0 0 0 27147 0 177147 0 0 0 PART I, LINE 3 FAIR MARKET VALUE COMPARISON OF SIMILAR ORGANIZATIONS FORM 990, PART VI, SECTION A, LINE 2 JOHN LONDON AND CATHERINE LONDON ARE MARRIED. FORM 990, PART VI, SECTION B, LINE 11B THE COMPLETED FORM 990 IS SENT TO THE BOARD OF DIRECTORS PRIOR TO FILING FOR REVIEW AND APPROVAL. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION DISTRIBUTES A CONFLICT OF INTEREST POLICY TO EACH BOARD MEMBER ANNUALLY AT THE BOARD MEETING. ALL STAFF AND BOARD MEMBERS ARE REQUIRED TO SIGN A CONFLICT OF INTEREST POLICY STATEMENT ON AN ANNUAL BASIS. ANY CONFLICTS THAT ARISE DURING THE COURSE OF THE YEAR ARE REQUIRED TO BE DISCLOSED AND RESOLVED BEFORE THE TRANSACTION IS COMPLETED. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION IS DETERMINED BY CONDUCTING A FAIR MARET VALUE COMPARISON OF OTHER ORGANIZATIONS BY THE BOARD CHAIR. FACTORS INCLUDE THE NUMBER OF HOURS WORKED AND THE BREADTH OF ROLES AND RESPONSIBILITIES. FORM 990, PART VI, SECTION C, LINE 18 THE ORGANIZATION'S FORM 990 IS AVAILABLE UPON REQUEST. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS IS MADE AVAILABLE UPON REQUEST. FORM 990, PART XII, LINE 2C: THE BOARD OF DIRECTORS IS CHARGED WITH OVERSIGHT IN REGARDS TO REVIEW OF THE FINANCIALS AND SELECTION OF THE AUDITOR.